ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
06 juil. 2022 07h12 HE | Zenith Capital Corp.
CALGARY, Alberta, July 06, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)
21 juin 2022 07h12 HE | Zenith Capital Corp.
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
10 mai 2022 08h15 HE | Zenith Capital Corp.
CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
22 févr. 2022 07h15 HE | Zenith Capital Corp.
CALGARY, Alberta, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) +...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
31 janv. 2022 08h00 HE | Zenith Capital Corp.
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors. Dr....
ZENITH-LOGO-RGB.jpg
Zenith 與 Newsoara Biopharma 宣佈擴大許可協議和投資
16 nov. 2021 06h58 HE | Zenith Capital Corp.
亞伯達省卡加利, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp.(「Zenith」或「公司」)今天宣佈 Zenith Capital 全資子公司 Zenith Epigenetics Ltd.(「Zenith Epigenetics」)剛與 Newsoara Biopharma Co., Ltd.(「Newsoara」)就...
ZENITH-LOGO-RGB.jpg
Zenith和Newsoara Biopharma宣布扩展许可和投资
16 nov. 2021 06h58 HE | Zenith Capital Corp.
阿尔伯塔省卡尔加里, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp.(以下简称“Zenith”)今日宣布,Zenith Capital的全资子公司Zenith Epigenetics Ltd.(以下简称“Zenith Epigenetics”)已与Newsoara Biopharma Co.,...
ZENITH-LOGO-RGB.jpg
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
15 nov. 2021 09h55 HE | Zenith Capital Corp.
CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
21 sept. 2021 08h00 HE | Zenith Capital Corp.
CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
ZENITH-LOGO-RGB.jpg
Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients
17 août 2021 08h00 HE | Zenith Capital Corp.
CALGARY, Alberta, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic...